Template:Epiglottitis Antibiotics: Difference between revisions
(Convert to {{AntibioticDose}} for SMW antibiotic-disease linking) |
|||
| Line 1: | Line 1: | ||
Coverage targets Streptococcus pneumoniae, Staphylococcus pyogenes, and Haemophilus influenzae, and H. parainfluenzae | Coverage targets Streptococcus pneumoniae, Staphylococcus pyogenes, and Haemophilus influenzae, and H. parainfluenzae | ||
====Immunocompetent==== | ====Immunocompetent==== | ||
* | *{{AntibioticDose|drug=Ceftriaxone|dose=2gm IV once daily|context=Immunocompetent}} (first line) OR | ||
* | *{{AntibioticDose|drug=Cefotaxime|dose=2gm (50mg/kg) IV three times daily|context=Immunocompetent}} OR | ||
* | *{{AntibioticDose|drug=Ampicillin/Sulbactam|dose=3g (50mg/kg) IV q 6 hours|context=Immunocompetent}} OR | ||
* | *{{AntibioticDose|drug=Levofloxacin|dose=750mg IV once daily|context=Immunocompetent}} | ||
*Consider | *Consider {{AntibioticDose|drug=Vancomycin|dose=15-20mg/kg IV|context=Immunocompetent, MRSA risk}} to any of the above if risk of [[MRSA]]<ref>Young LS, Price CS. Complicated adult epiglottitis due to methicillin-resistant Staphylococcus aureus. Am J Otolaryngol. Nov-Dec 2007;28(6):441-3.</ref> | ||
====Immunocompromised==== | ====Immunocompromised==== | ||
Coverage should extend to all of the typical organisms above as well as Pseudomonas, M. tuberculosis, and C. albicans | Coverage should extend to all of the typical organisms above as well as Pseudomonas, M. tuberculosis, and C. albicans | ||
* | *{{AntibioticDose|drug=Cefepime|dose=2g (50/kg) IV q8 hours|context=Immunocompromised}} AND {{AntibioticDose|drug=Vancomycin|dose=15mg/kg IV q6 hours|context=Immunocompromised}} | ||
Revision as of 20:50, 19 March 2026
Coverage targets Streptococcus pneumoniae, Staphylococcus pyogenes, and Haemophilus influenzae, and H. parainfluenzae
Immunocompetent
- Ceftriaxone 2gm IV once daily (first line) OR
- Cefotaxime 2gm (50mg/kg) IV three times daily OR
- Ampicillin/Sulbactam 3g (50mg/kg) IV q 6 hours OR
- Levofloxacin 750mg IV once daily
- Consider Vancomycin 15-20mg/kg IV to any of the above if risk of MRSA[1]
Immunocompromised
Coverage should extend to all of the typical organisms above as well as Pseudomonas, M. tuberculosis, and C. albicans
- Cefepime 2g (50/kg) IV q8 hours AND Vancomycin 15mg/kg IV q6 hours
- ↑ Young LS, Price CS. Complicated adult epiglottitis due to methicillin-resistant Staphylococcus aureus. Am J Otolaryngol. Nov-Dec 2007;28(6):441-3.